Julio Licinio

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/911943/publications.pdf

Version: 2024-02-01

344 papers 31,451 citations

7096 78 h-index 169 g-index

402 all docs 402 docs citations

402 times ranked 38032 citing authors

#	Article	IF	CITATIONS
1	Chronic post-COVID-19 syndrome and chronic fatigue syndrome: Is there a role for extracorporeal apheresis?. Molecular Psychiatry, 2022, 27, 34-37.	7.9	59
2	Biogeography of the large intestinal mucosal and luminal microbiome in cynomolgus macaques with depressive-like behavior. Molecular Psychiatry, 2022, 27, 1059-1067.	7.9	17
3	Impact of CYP2C19 metaboliser status on SSRI response: a retrospective study of 9500 participants of the Australian Genetics of Depression Study. Pharmacogenomics Journal, 2022, 22, 130-135.	2.0	16
4	The effect of cognitive behavioral stress management on perceived stress, biological stress markers and weight loss/regain, from a diet-induced weight loss program: A randomized controlled trial. Comprehensive Psychoneuroendocrinology, 2022, 10, 100124.	1.7	1
5	Edaravone ameliorates depressive and anxiety-like behaviors via Sirt1/Nrf2/HO-1/Gpx4 pathway. Journal of Neuroinflammation, 2022, 19, 41.	7.2	142
6	The gut microbiome and mental health: advances in research and emerging priorities. Molecular Psychiatry, 2022, 27, 1908-1919.	7.9	39
7	ADORA1-driven brain-sympathetic neuro-adipose connections control body weight and adipose lipid metabolism. Molecular Psychiatry, 2021, 26, 2805-2819.	7.9	8
8	The gut microbiome modulates gut–brain axis glycerophospholipid metabolism in a region-specific manner in a nonhuman primate model of depression. Molecular Psychiatry, 2021, 26, 2380-2392.	7.9	102
9	A Brain Capital Grand Strategy: toward economic reimagination. Molecular Psychiatry, 2021, 26, 3-22.	7.9	41
10	Rare Functional Variants Associated with Antidepressant Remission in Mexican-Americans. Journal of Affective Disorders, 2021, 279, 491-500.	4.1	3
11	Advances in autism research, 2021: continuing to decipher the secrets of autism. Molecular Psychiatry, 2021, 26, 1426-1428.	7.9	O
12	The ERK phosphorylation levels in the amygdala predict anxiety symptoms in humans and MEK/ERK inhibition dissociates innate and learned defensive behaviors in rats. Molecular Psychiatry, 2021, 26, 7257-7269.	7.9	15
13	Activation of septal OXTr neurons induces anxiety- but not depressive-like behaviors. Molecular Psychiatry, 2021, 26, 7270-7279.	7.9	12
14	Medical student knowledge and critical appraisal of machine learning: a multicentre international crossâ€sectional study. Internal Medicine Journal, 2021, 51, 1539-1542.	0.8	8
15	Climate change and mental health: a commentary. Discover Mental Health, 2021, 1, 1.	2.0	O
16	Molecular Psychiatry special issue: advances in Alzheimer's disease. Molecular Psychiatry, 2021, 26, 5467-5470.	7.9	2
17	Extracorporeal apheresis therapy for Alzheimer diseaseâ€"targeting lipids, stress, and inflammation. Molecular Psychiatry, 2020, 25, 275-282.	7.9	16
18	Using behaviour change theory to inform an innovative digital recruitment strategy in a mental health research setting. Journal of Psychiatric Research, 2020, 120, 1-13.	3.1	4

#	Article	IF	CITATIONS
19	Landscapes of bacterial and metabolic signatures and their interaction in major depressive disorders. Science Advances, 2020, 6, .	10.3	178
20	Advances in schizophrenia research: glycobiology, white matter abnormalities, and their interactions. Molecular Psychiatry, 2020, 25, 3116-3118.	7.9	2
21	Molecular Psychiatry, August 2020: new impact factor, and highlights of recent advances in psychiatry, including an overview of the brain's response to stress during infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Molecular Psychiatry, 2020, 25, 1606-1610.	7.9	0
22	The COVID-19 pandemic and epidemiologic insights from recession-related suicide mortality. Molecular Psychiatry, 2020, 25, 3445-3447.	7.9	20
23	Offensive Behavior, Striatal Glutamate Metabolites, and Limbic–Hypothalamic–Pituitary–Adrenal Responses to Stress in Chronic Anxiety. International Journal of Molecular Sciences, 2020, 21, 7440.	4.1	10
24	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the neuroendocrine stress axis. Molecular Psychiatry, 2020, 25, 1611-1617.	7.9	70
25	Cohort profile: the Australian genetics of depression study. BMJ Open, 2020, 10, e032580.	1.9	40
26	Advances in depression research: second special issue, 2020, with highlights on biological mechanisms, clinical features, co-morbidity, genetics, imaging, and treatment. Molecular Psychiatry, 2020, 25, 1356-1360.	7.9	10
27	Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression. Advanced Science, 2020, 7, 1902862.	11.2	99
28	Advances in research on stress and behavior: special issue, 2020. Molecular Psychiatry, 2020, 25, 916-917.	7.9	2
29	Pilot trial of a group cognitive behavioural therapy program for comorbid depression and obesity. BMC Psychology, 2020, 8, 34.	2.1	5
30	Advances in schizophrenia research: first special issue, 2020. Molecular Psychiatry, 2020, 25, 699-700.	7.9	3
31	Advances in depression research: special issue, 2020, with three research articles by Paul Greengard. Molecular Psychiatry, 2020, 25, 1156-1158.	7.9	2
32	Psychiatric Disorders and Bone Emphasizing Mechanistic Trends. , 2020, , 33-42.		0
33	Perturbed Microbial Ecology in Myasthenia Gravis: Evidence from the Gut Microbiome and Fecal Metabolome. Advanced Science, 2019, 6, 1901441.	11.2	55
34	Post-Traumatic Stress Disorder Chronification via Monoaminooxidase and Cortisol Metabolism. Hormone and Metabolic Research, 2019, 51, 618-622.	1.5	11
35	Determinants for Meaningful Clinical Improvement of Pain and Health-Related Quality of Life After Spinal Cord Stimulation for Chronic Intractable Pain. Neuromodulation, 2019, 22, 280-289.	0.8	16
36	Congenital Leptin Deficiency and Leptin Gene Missense Mutation Found in Two Colombian Sisters with Severe Obesity. Genes, 2019, 10, 342.	2.4	21

#	Article	IF	CITATIONS
37	Social network theory and rising suicide rates in the USA. Lancet, The, 2019, 393, 1801.	13.7	3
38	Mice lacking Casp1, Ifngr and Nos2 genes exhibit altered depressive- and anxiety-like behaviour, and gut microbiome composition. Scientific Reports, 2019, 9, 6456.	3.3	15
39	From Allostatic Load to Allostatic State—An Endogenous Sympathetic Strategy to Deal With Chronic Anxiety and Stress?. Frontiers in Behavioral Neuroscience, 2019, 13, 47.	2.0	25
40	AGRP neurons modulate fasting-induced anxiolytic effects. Translational Psychiatry, 2019, 9, 111.	4.8	35
41	The gut microbiome from patients with schizophrenia modulates the glutamate-glutamine-GABA cycle and schizophrenia-relevant behaviors in mice. Science Advances, 2019, 5, eaau8317.	10.3	446
42	A Neuroethics Framework for the Australian Brain Initiative. Neuron, 2019, 101, 365-369.	8.1	11
43	Effect of medical student debt on mental health, academic performance and specialty choice: a systematic review. BMJ Open, 2019, 9, e029980.	1.9	111
44	Inherited anxiety-related parent–infant dyads alter LHPA activity. Stress, 2019, 22, 27-35.	1.8	3
45	Bullying and sexual abuse and their association with harmful behaviours, antidepressant use and health-related quality of life in adulthood: a population-based study in South Australia. BMC Public Health, 2019, 19, 26.	2.9	7
46	Shared associations between histories of victimisation among people with eating disorder symptoms and higher weight. Australian and New Zealand Journal of Psychiatry, 2019, 53, 540-549.	2.3	5
47	Neuroimmunomodulation in Major Depressive Disorder: Focus on Caspase 1, Inducible Nitric Oxide Synthase, and Interferon-Gamma. Molecular Neurobiology, 2019, 56, 4288-4305.	4.0	62
48	Stress-inducible-stem cells: a new view on endocrine, metabolic and mental disease?. Molecular Psychiatry, 2019, 24, 2-9.	7.9	21
49	The depressed heart. Heart and Mind (Mumbai, India), 2019, 3, 35.	0.6	7
50	Investigation of short tandem repeats in major depression using whole-genome sequencing data. Journal of Affective Disorders, 2018, 232, 305-309.	4.1	10
51	Urinary Lipidomics: evidence for multiple sources and sexual dimorphism in healthy individuals. Pharmacogenomics Journal, 2018, 18, 331-339.	2.0	10
52	When should governments increase the supply of psychiatric beds?. Molecular Psychiatry, 2018, 23, 796-800.	7.9	44
53	Genetic clustering of depressed patients and normal controls based on single-nucleotide variant proportion. Journal of Affective Disorders, 2018, 227, 450-454.	4.1	7
54	Improving cardiovascular health and quality of life in people with severe mental illness: study protocol for a randomised controlled trial. Trials, 2018, 19, 366.	1.6	5

#	Article	IF	CITATIONS
55	The Microbiotaâ€Inflammasome Hypothesis of Major Depression. BioEssays, 2018, 40, e1800027.	2.5	91
56	Low-frequency and rare variants may contribute to elucidate the genetics of major depressive disorder. Translational Psychiatry, 2018, 8, 70.	4.8	25
57	Can deinstitutionalisation contribute to exclusion?. Lancet, The, 2018, 391, 2210.	13.7	1
58	Resilience and Psychological Distress in Psychology and Medical Students. Academic Psychiatry, 2017, 41, 185-188.	0.9	91
59	Role of the IL-1 Pathway in Dopaminergic Neurodegeneration and Decreased Voluntary Movement. Molecular Neurobiology, 2017, 54, 4486-4495.	4.0	38
60	Single-nucleotide variant proportion in genes: a new concept to explore major depression based on DNA sequencing data. Journal of Human Genetics, 2017, 62, 577-580.	2.3	11
61	Whole-genome single nucleotide variant distribution on genomic regions and its relationship to major depression. Psychiatry Research, 2017, 252, 75-79.	3.3	12
62	A latent genetic subtype of major depression identified by whole-exome genotyping data in a Mexican-American cohort. Translational Psychiatry, 2017, 7, e1134-e1134.	4.8	19
63	Biological and behavioural antidepressant treatment responses with the selective serotonin reuptake inhibitor fluoxetine can be determined by the environment. Molecular Psychiatry, 2017, 22, 484-484.	7.9	4
64	A novel strategy for clustering major depression individuals using whole-genome sequencing variant data. Scientific Reports, 2017, 7, 44389.	3.3	14
65	Circumcision does not alter long-term glucocorticoids accumulation or psychological effects associated with trauma- and stressor-related disorders. Translational Psychiatry, 2017, 7, e1063-e1063.	4.8	9
66	Digital footprints: facilitating large-scale environmental psychiatric research in naturalistic settings through data from everyday technologies. Molecular Psychiatry, 2017, 22, 164-169.	7.9	53
67	SSRI antidepressant use potentiates weight gain in the context of unhealthy lifestyles: results from a 4-year Australian follow-up study. BMJ Open, 2017, 7, e016224.	1.9	17
68	Persistent LHPA Activation in German Individuals Raised in an Overprotective Parental Behavior. Scientific Reports, 2017, 7, 2778.	3.3	11
69	The PHF21B gene is associated with major depression and modulates the stress response. Molecular Psychiatry, 2017, 22, 1015-1025.	7.9	56
70	Population levels of wellbeing and the association with social capital. BMC Psychology, 2017, 5, 23.	2.1	9
71	Investigation of copy number variation in subjects with major depression based on whole-genome sequencing data. Journal of Affective Disorders, 2017, 220, 38-42.	4.1	9
72	Leptin signals via TGFB1 to promote metastatic potential and stemness in breast cancer. PLoS ONE, 2017, 12, e0178454.	2.5	46

#	Article	IF	Citations
73	Genetic overlap between type 2 diabetes and depression in Swedish and Danish twin registries. Molecular Psychiatry, 2016, 21, 903-909.	7.9	50
74	Is increased antidepressant exposure a contributory factor to the obesity pandemic?. Translational Psychiatry, 2016, 6, e759-e759.	4.8	105
75	Gut microbiome remodeling induces depressive-like behaviors through a pathway mediated by the host's metabolism. Molecular Psychiatry, 2016, 21, 786-796.	7.9	1,397
76	Monika Ehrhart-Bornstein, 1959–2015. Molecular Psychiatry, 2016, 21, 588-589.	7.9	0
77	From gut dysbiosis to altered brain function and mental illness: mechanisms and pathways. Molecular Psychiatry, 2016, 21, 738-748.	7.9	683
78	Inflammasome signaling affects anxiety- and depressive-like behavior and gut microbiome composition. Molecular Psychiatry, 2016, 21, 797-805.	7.9	400
79	The effects of stress on brain and adrenal stem cells. Molecular Psychiatry, 2016, 21, 590-593.	7.9	19
80	Contribution of IL-10 and its -592 A/C polymorphism to cognitive functions in first-episode drug-naive schizophrenia. Brain, Behavior, and Immunity, 2016, 57, 116-124.	4.1	36
81	Serotonergic neurons derived from induced pluripotent stem cells (iPSCs): a new pathway for research on the biology and pharmacology of major depression. Molecular Psychiatry, 2016, 21, 1-2.	7.9	34
82	APOE*E2 allele delays age of onset in PSEN1 E280A Alzheimer's disease. Molecular Psychiatry, 2016, 21, 916-924.	7.9	89
83	Trial for the Prevention of Depression (TriPoD) in final-year secondary students: study protocol for a cluster randomised controlled trial. Trials, 2015, 16, 451.	1.6	16
84	2.2Translational Research in Endocrinology and Neuroimmunology Applied to Depression. , $2015,$, $119-131.$		1
85	Valproic acid enhances neuronal differentiation of sympathoadrenal progenitor cells. Molecular Psychiatry, 2015, 20, 941-950.	7.9	26
86	Chronic administration of anticonvulsants but not antidepressants impairs bone strength: clinical implications. Translational Psychiatry, 2015, 5, e576-e576.	4.8	12
87	Temporal Gene Expression in the Hippocampus and Peripheral Organs to Endotoxin-Induced Systemic Inflammatory Response in Caspase-1-Deficient Mice. NeuroImmunoModulation, 2015, 22, 263-273.	1.8	4
88	Qualitative Literature Review of the Prevalence of Depression in Medical Students Compared to Students in Non-medical Degrees. Academic Psychiatry, 2015, 39, 293-299.	0.9	38
89	Molecular Psychiatry: Twenty years of progress from bench to clinic. Molecular Psychiatry, 2015, 20, 657-657.	7.9	0
90	Molecular Psychiatry: 20 Years. Molecular Psychiatry, 2015, 20, 545-547.	7.9	0

#	Article	IF	Citations
91	Response to Uher et al American Journal of Psychiatry, 2015, 172, 396-398.	7.2	1
92	Emotional and psychological trauma in refugees arriving in Germany in 2015. Molecular Psychiatry, 2015, 20, 1483-1484.	7.9	69
93	Leptin treatment: Facts and expectations. Metabolism: Clinical and Experimental, 2015, 64, 146-156.	3.4	168
94	Whole Exome Sequencing of Extreme Morbid Obesity Patients: Translational Implications for Obesity and Related Disorders. Genes, 2014, 5, 709-725.	2.4	19
95	Leptin Mediates the Increase in Blood Pressure Associated with Obesity. Cell, 2014, 159, 1404-1416.	28.9	288
96	Launching the â€~War on Mental Illness'. Molecular Psychiatry, 2014, 19, 1-5.	7.9	26
97	Clinical Outcomes and Genome-Wide Association for a Brain Methylation Site in an Antidepressant Pharmacogenetics Study in Mexican Americans. American Journal of Psychiatry, 2014, 171, 1297-1309.	7.2	33
98	Plasma leptin concentrations are highly correlated to emotional states throughout the day. Translational Psychiatry, 2014, 4, e475-e475.	4.8	23
99	Leptin Signaling and Hyperparathyroidism: Clinical and Genetic Associations. Journal of the American College of Surgeons, 2014, 218, 1239-1250e4.	0.5	8
100	Lipidomic profiling before and after Roux-en-Y gastric bypass in obese patients with diabetes. Pharmacogenomics Journal, 2014, 14, 201-207.	2.0	39
101	Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico. Pharmacogenomics Journal, 2013, 13, 567-572.	2.0	22
102	Effects of Leptin Deficiency and Replacement on Cerebellar Response to Food-Related Cues. Cerebellum, 2013, 12, 59-67.	2.5	29
103	Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics Journal, 2013, 13, 514-522.	2.0	380
104	Molecular pathways involved in the improvement of non-alcoholic fatty liver disease. Journal of Molecular Endocrinology, 2013, 51, 167-179.	2.5	15
105	Pathological parainflammation and endoplasmic reticulum stress in depression: potential translational targets through the CNS insulin, klotho and PPAR- \hat{l}^3 systems. Molecular Psychiatry, 2013, 18, 154-165.	7.9	104
106	US shutdown should spur other nations. Nature, 2013, 503, 198-198.	27.8	0
107	Increased rate of depression and psychosomatic symptoms in Jewish migrants from the post-Soviet-Union to Germany in the 3rd generation after the Shoa. Translational Psychiatry, 2013, 3, e241-e241.	4.8	19
108	A novel conceptual framework for psychiatry: vertically and horizontally integrated approaches to redundancy and pleiotropism that co-exist with a classification of symptom clusters based on DSM-5. Molecular Psychiatry, 2013, 18, 846-848.	7.9	17

#	Article	IF	Citations
109	Adipokines: Soluble Factors from Adipose Tissue Implicated in Cancer., 2013,, 71-97.		1
110	Abstract C64: Leptin increases the metastatic potential of breast cancer cells., 2013,,.		0
111	Prediction of susceptibility to major depression by a model of interactions of multiple functional genetic variants and environmental factors. Molecular Psychiatry, 2012, 17, 624-633.	7.9	79
112	Absence of evidence for bornavirus infection in schizophrenia, bipolar disorder and major depressive disorder. Molecular Psychiatry, 2012, 17, 486-493.	7.9	82
113	Chromaffin cells: the peripheral brain. Molecular Psychiatry, 2012, 17, 354-358.	7.9	33
114	Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arquivos Brasileiros De Endocrinologia E Metabologia, 2012, 56, 597-607.	1.3	152
115	Dopamine D2/D3 receptor availability in genetically leptin-deficient patients after long-term leptin replacement. Molecular Psychiatry, 2012, 17, 352-353.	7.9	10
116	Dietary, Endocrine, and Metabolic Factors in the Development of Colorectal Cancer. Journal of Gastrointestinal Cancer, 2012, 43, 13-19.	1.3	39
117	Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian Journal of Endocrinology and Metabolism, 2012, 16, 549.	0.4	99
118	CYP2C9 allele frequency differences between populations of Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics Journal, 2011, 11, 108-112.	2.0	46
119	Improving the efficacy of translational medicine by optimally integrating health care, academia and industry. Nature Medicine, 2011, 17, 1567-1569.	30.7	41
120	Associations between adipokines and obesity-related cancer. Frontiers in Bioscience - Landmark, 2011, 16, 1634.	3.0	138
121	Sequence polymorphisms of MC1R gene and their association with depression and antidepressant response. Psychiatric Genetics, 2011, 21, 14-18.	1.1	22
122	Ten years of leptin replacement therapy. Obesity Reviews, 2011, 12, e315-23.	6.5	108
123	Long-term body weight outcomes of antidepressant–environment interactions. Molecular Psychiatry, 2011, 16, 265-272.	7.9	30
124	Short-Term Plasticity of Gray Matter Associated with Leptin Deficiency and Replacement. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1212-E1220.	3.6	39
125	Reply to Liu et al.: Hypothalamic control of islets. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, E1391-E1391.	7.1	0
126	cGMP Signaling, Phosphodiesterases and Major Depressive Disorder. Current Neuropharmacology, 2011, 9, 715-727.	2.9	59

#	Article	IF	Citations
127	Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11Â-hydroxysteroid dehydrogenase. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 13722-13727.	7.1	45
128	Dynamics of plasma proteome during leptin-replacement therapy in genetically based leptin deficiency. Pharmacogenomics Journal, 2011, 11, 174-190.	2.0	7
129	Translational Psychiatry: leading the transition from the cesspool of devastation to a place where the grass is really greener. Translational Psychiatry, 2011, 1, e1-e1.	4.8	23
130	Advances in depression research: 2011. Molecular Psychiatry, 2011, 16, 686-687.	7.9	14
131	Why does the United States need a national center for new cures?. Molecular Psychiatry, 2011, 16, 882-884.	7.9	4
132	Pharmacogenomics of antidepressant treatment effects. Dialogues in Clinical Neuroscience, 2011, 13, 63-71.	3.7	36
133	The procognitive effects of leptin in the brain and their clinical implications. International Journal of Clinical Practice, 2010, 64, 1808-1812.	1.7	93
134	Potential diagnostic markers for postpartum depression point out to altered immune signaling. Molecular Psychiatry, 2010, 15, 1-1.	7.9	19
135	Messages from hypothesis-driven genotyping: the case of schizoaffective disorder, bipolar type. Molecular Psychiatry, 2010, 15, 113-114.	7.9	1
136	Genetic repositories for the study of major psychiatric conditions: what do we know about ethnic minorities' genetic vulnerability?. Molecular Psychiatry, 2010, 15, 970-975.	7.9	9
137	Brain-derived neurotrophic factor in depression: a male problem?. Molecular Psychiatry, 2010, 15, 227-227.	7.9	6
138	Pharmacogenomics of antidepressants: what is next?. Molecular Psychiatry, 2010, 15, 445-445.	7.9	6
139	Premier je suis, Second je fus, Molecular Psychiatry ne change. Molecular Psychiatry, 2010, 15, 777-777.	7.9	1
140	The First International Conference on Translational Medicine. Molecular Psychiatry, 2010, 15, 878-879.	7.9	5
141	Integrating common and rare genetic variation in diverse human populations. Nature, 2010, 467, 52-58.	27.8	2,625
142	Concrete helix recalls smallpox win. Nature, 2010, 468, 173-173.	27.8	2
143	Congenital leptin deficiency: diagnosis and effects of leptin replacement therapy. Arquivos Brasileiros De Endocrinologia E Metabologia, 2010, 54, 690-697.	1.3	77
144	Pathophysiological basis of cardiovascular disease and depression: a chicken-and-egg dilemma. Revista Brasileira De Psiquiatria, 2010, 32, 181-191.	1.7	22

#	Article	IF	CITATIONS
145	Leptin Replacement Prevents Weight Loss-Induced Metabolic Adaptation in Congenital Leptin-Deficient Patients. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 851-855.	3.6	53
146	Candidate Biomarkers for Systemic Inflammatory Response Syndrome and Inflammation: A Pathway for Novel Translational Therapeutics. NeuroImmunoModulation, 2010, 17, 359-368.	1.8	5
147	Induction of apoptosis and cell cycle arrest in L-1210 murine lymphoblastic leukaemia cells by (2 <i>E</i>)-3-(2-naphthyl)-1-(3′-methoxy-4′-hydroxy-phenyl)-2-propen-1-one. Journal of Pharmacy and Pharmacology, 2010, 62, 1128-1136.	2.4	22
148	Leptin Levels and Alzheimer Disease. JAMA - Journal of the American Medical Association, 2010, 303, 1478.	7.4	18
149	Association of PDE11A global haplotype with major depression and antidepressant drug response. Neuropsychiatric Disease and Treatment, 2009, 5, 163.	2.2	24
150	Chronic fluoxetine treatment increases daytime melatonin synthesis in the rodent. Clinical Pharmacology: Advances and Applications, 2009, 1, 1.	1.2	2
151	Cellular Immunity Before and After Leptin Replacement Therapy. Journal of Pediatric Endocrinology and Metabolism, 2009, 22, 1069-74.	0.9	16
152	Novel Sequence Variations in the Brain-Derived Neurotrophic Factor Gene and Association With Major Depression and Antidepressant Treatment Response. Archives of General Psychiatry, 2009, 66, 488.	12.3	151
153	Deconvolution of Insulin Secretion, Insulin Hepatic Extraction Post-hepatic Delivery Rates and Sensitivity during 24-hour Standardized Meals: Time Course of Glucose Homeostasis in Leptin Replacement Treatment. Hormone and Metabolic Research, 2009, 41, 142-151.	1.5	27
154	Effects of Leptin Replacement on Risk Factors for Cardiovascular Disease in Genetically Leptin-deficient Subjects. Hormone and Metabolic Research, 2009, 41, 164-167.	1.5	12
155	Leptin and insulin sensitivity: reply to Oral and Burant. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E396-E396.	3 . 5	0
156	Global meta-analysis of the C-11377G alteration in the ADIPOQ gene indicates the presence of population-specific effects: challenge for global health initiatives. Pharmacogenomics Journal, 2009, 9, 42-48.	2.0	14
157	Congenital leptin deficiency and thyroid function. Thyroid Research, 2009, 2, 11.	1.5	27
158	Update on Molecular Psychiatry: new publication guidelines and new ways to stay current. Molecular Psychiatry, 2009, 14, 463-464.	7.9	0
159	Sequence variations of ABCB1, SLC6A2, SLC6A3, SLC6A4, CREB1, CRHR1 and NTRK2: association with major depression and antidepressant response in Mexican-Americans. Molecular Psychiatry, 2009, 14, 1105-1118.	7.9	150
160	Repeated antidepressant therapy increases cyclic GMP signaling in rat hippocampus. Neuroscience Letters, 2009, 466, 149-153.	2.1	12
161	Phosphodiesterase genes and antidepressant treatment response: A review. Annals of Medicine, 2009, 41, 177-185.	3.8	29
162	Chronic imipramine downregulates cyclic AMP signaling in rat hippocampus. NeuroReport, 2009, 20, 307-311.	1.2	9

#	Article	IF	Citations
163	Magneto-orientational properties of ionically stabilized aqueous dispersions of Ni(OH)2 nanoplatelets. European Physical Journal E, 2008, 26, 355-360.	1.6	3
164	Polymorphisms in inflammation-related genes are associated with susceptibility to major depression and antidepressant response. Molecular Psychiatry, 2008, 13, 800-812.	7.9	270
165	Is the Worldwide Epidemic of Obesity a Communicable Feature of Globalization?. Experimental and Clinical Endocrinology and Diabetes, 2008, 116, S30-S32.	1.2	22
166	Changes in insulin sensitivity during leptin replacement therapy in leptin-deficient patients. American Journal of Physiology - Endocrinology and Metabolism, 2008, 295, E1401-E1408.	3.5	46
167	Radioiodine Treatment Triggers Security Alarms: Case Report and Review of Literature. Journal of Nuclear Medicine, 2008, 49, 337-337.	5.0	5
168	Reciprocal Production of Adiponectin and C-reactive Protein in Coronary Circulation of Patients with and without Coronary Artery Disease. Hormone and Metabolic Research, 2008, 40, 580-580.	1.5	0
169	Effects of Leptin on Lipid Metabolism. Hormone and Metabolic Research, 2008, 40, 572-574.	1.5	16
170	Elevated Stress-Hemoconcentration in Major Depression Is Normalized by Antidepressant Treatment: Secondary Analysis from a Randomized, Double-Blind Clinical Trial and Relevance to Cardiovascular Disease Risk. PLoS ONE, 2008, 3, e2350.	2.5	27
171	Leptin Replacement Improves Cognitive Development. PLoS ONE, 2008, 3, e3098.	2.5	120
172	Ecological Studies of Antidepressant Treatment and Suicidal Risks. Harvard Review of Psychiatry, 2007, 15, 133-145.	2.1	65
173	The Metabolic Syndrome - A Global Challenge for Prevention. Hormone and Metabolic Research, 2007, 39, 777-780.	1.5	58
174	Caspase 1 deficiency reduces inflammation-induced brain transcription. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 7205-7210.	7.1	36
175	Leptin replacement alters brain response to food cues in genetically leptin-deficient adults. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18276-18279.	7.1	193
176	Suicidality Scores During Double-Blind Fluoxetine and Desipramine Treatment in Mexican Americans. Journal of Clinical Psychopharmacology, 2007, 27, 99-102.	1.4	4
177	The brain-derived neurotrophic factor rs6265 (Val66Met) polymorphism and depression in Mexican-Americans. NeuroReport, 2007, 18, 1291-1293.	1.2	83
178	Effects of leptin on intake of specific micro- and macronutrients in a woman with leptin gene deficiency studied off and on leptin at stable body weight. Appetite, 2007, 49, 594-599.	3.7	24
179	Pharmacogenomics of neuroimmune interactions in human psychiatric disorders. Experimental Physiology, 2007, 92, 807-811.	2.0	21
180	Effects of leptin replacement on macro- and micronutrient preferences. International Journal of Obesity, 2007, 31, 1859-1863.	3.4	17

#	Article	IF	CITATIONS
181	Modeling of the Temporal Patterns of Fluoxetine Prescriptions and Suicide Rates in the United States. PLoS Medicine, 2006, 3, e190.	8.4	41
182	Relationship Between Increasing Body Weight, Insulin Resistance, Inflammation, Adipocytokine Leptin, and Coronary Circulatory Function. Journal of the American College of Cardiology, 2006, 47, 1188-1195.	2.8	215
183	Editorial [Hot Topic: Pharmacogenetic and Pharmacogenomics (Guest Editors: A. LLerena and J. Licinio)]. Current Drug Targets, 2006, 7, 1639-1640.	2.1	0
184	Molecular Psychiatry: the highest Immediacy Index in the field of psychiatry. Molecular Psychiatry, 2006, 11, 324-324.	7.9	5
185	Human food preferences are associated with a 5-HT2A serotonergic receptor polymorphism. Molecular Psychiatry, 2006, 11, 889-891.	7.9	24
186	Approaching the shared biology of obesity and depression: the stress axis as the locus of gene–environment interactions. Molecular Psychiatry, 2006, 11, 892-902.	7.9	228
187	150 years of Sigmund Freud: what would Freud have said about the obesity epidemic?. Molecular Psychiatry, 2006, 11, 1070-1072.	7.9	23
188	New directions for 2006. Pharmacogenomics Journal, 2006, 6, 1-1.	2.0	7
189	Authors' Response to Hockey and Reidak. PLoS Medicine, 2006, 3, e407.	8.4	0
190	Fluoxetine and Suicide Rates: Author's Reply. PLoS Medicine, 2006, 3, e504.	8.4	0
191	Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 15124-15129.	7.1	147
192	Pulsatile and Diurnal Leptin Rhythms., 2006,, 247-262.		1
193	CYP2C9 and clinical response to antidepressant drugs in Mexican-Americans. Clinical Pharmacology and Therapeutics, 2005, 77, P24-P24.	4.7	1
194	Depression, antidepressants and suicidality: a critical appraisal. Nature Reviews Drug Discovery, 2005, 4, 165-171.	46.4	89
195	The evolution of signaling complexity suggests a mechanism for reducing the genomic search space in human association studies. Molecular Psychiatry, 2005, 10, 14-26.	7.9	13
196	Ten years of Molecular Psychiatry. Molecular Psychiatry, 2005, 10, 1-2.	7.9	3
197	Peripheral is Central to the question. Molecular Psychiatry, 2005, 10, 421-422.	7.9	13
198	Pharmacogenomics in psychiatry: clinical issues to be considered. Molecular Psychiatry, 2005, 10, 615-615.	7.9	10

#	Article	IF	Citations
199	The experience of bipolar disorder: a personal perspective on the impact of mood disorder symptoms. Molecular Psychiatry, 2005, 10, 827-830.	7.9	8
200	Elevated cortisol levels and increased rates of diabetes and mood symptoms in Soviet Union-born Jewish immigrants to Germany. Molecular Psychiatry, 2005, 10, 974-975.	7.9	31
201	Pharmacogenomics in psychiatry: genomic considerations. Molecular Psychiatry, 2005, 10, 713-713.	7.9	3
202	Depression and anxiety symptoms in diabetic patients on continuous subcutaneous insulin infusion (CSII). Molecular Psychiatry, 2005, 10, 975-976.	7.9	16
203	Pharmacogenomics Education: International Society of Pharmacogenomics Recommendations for Medical, Pharmaceutical, and Health Schools Deans of Education. Pharmacogenomics Journal, 2005, 5, 221-225.	2.0	119
204	Development of a PCR-based strategy for <i>CYP2D6</i> genotyping including gene multiplication of worldwide potential use. BioTechniques, 2005, 39, S571-S574.	1.8	68
205	Internal Transcribed Spacer rRNA Gene-Based Phylogenetic Reconstruction Using Algorithms with Local and Global Sequence Alignment for Black Yeasts and Their Relatives. Journal of Clinical Microbiology, 2005, 43, 2816-2823.	3.9	31
206	Effect of Leptin Replacement on Brain Structure in Genetically Leptin-Deficient Adults. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2851-2854.	3.6	169
207	Cardiac implications of increased arterial entry and reversible 24-h central and peripheral norepinephrine levels in melancholia. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 8303-8308.	7.1	90
208	An Explanation for the Placebo Effect?. Science, 2005, 307, 1411-1412.	12.6	16
209	Microanalysis of eating behavior of three leptin deficient adults treated with leptin therapy. Appetite, 2005, 45, 75-80.	3.7	51
210	Major Depression Is Associated with Significant Diurnal Elevations in Plasma Interleukin-6 Levels, a Shift of Its Circadian Rhythm, and Loss of Physiological Complexity in Its Secretion: Clinical Implications. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2522-2530.	3.6	330
211	Simultaneous and Continuous 24-Hour Plasma and Cerebrospinal Fluid Leptin Measurements: Dissociation of Concentrations in Central and Peripheral Compartments. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 258-265.	3.6	32
212	Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 4531-4536.	7.1	445
213	Alterations in the dynamics of circulating ghrelin, adiponectin, and leptin in human obesity. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 10434-10439.	7.1	308
214	From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nature Reviews Drug Discovery, 2004, 3, 136-151.	46.4	192
215	A leadership crisis in American psychiatry. Molecular Psychiatry, 2004, 9, 1-1.	7.9	23
216	St John's wort and imipramine-induced gene expression profiles identify cellular functions relevant to antidepressant action and novel pharmacogenetic candidates for the phenotype of antidepressant treatment response. Molecular Psychiatry, 2004, 9, 237-251.	7.9	54

#	Article	IF	Citations
217	Translational research in psychiatry: pitfalls and opportunities for career development. Molecular Psychiatry, 2004, 9, 117-117.	7.9	7
218	Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Molecular Psychiatry, 2004, 9, 442-473.	7.9	661
219	Back to where it all started: monoamines and behaviorâ€"from drug responses to genes. Molecular Psychiatry, 2004, 9, 427-427.	7.9	4
220	Association of a corticotropin-releasing hormone receptor 1 haplotype and antidepressant treatment response in Mexican-Americans. Molecular Psychiatry, 2004, 9, 1075-1082.	7.9	159
221	Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics Journal, 2004, 4, 403-406.	2.0	62
222	An experimental therapeutic approach to genetically-based obesity leptin replacement therapy resolves morbid obesity, hypogonadism and diabetes mellitus in leptin-deficient adults. Clinical Pharmacology and Therapeutics, 2004, 75, P11.	4.7	0
223	CYP2D6 poor metabolizers in depressed women of Mexican origin. Clinical Pharmacology and Therapeutics, 2004, 75, P41.	4.7	0
224	Clinical Implications of Genetic Polymorphism of <i>CYP2D6</i> in Mexican Americans. Annals of Internal Medicine, 2004, 140, W-48.	3.9	4
225	Molecular Psychiatry in 2003: editorial decisions and feature articles. Molecular Psychiatry, 2003, 8, 123-124.	7.9	0
226	Molecular psychiatry: moving away from one-polymorphism genetic association studies. Molecular Psychiatry, 2003, 8, 247-247.	7.9	9
227	Lilly–Molecular Psychiatry Award: 2003 winners and 2004 call for submissions. Molecular Psychiatry, 2003, 8, 567-567.	7.9	0
228	Data from the Northern Finland 1966 Birth Cohort support an association between depression and immune function. Molecular Psychiatry, 2003, 8, 711-712.	7.9	1
229	The Pharmacogenomics Journal: the official journal of the International Society of Pharmacogenomics (ISP). Pharmacogenomics Journal, 2003, 3, 1-1.	2.0	5
230	Sequence and function in pharmacogenomics. Pharmacogenomics Journal, 2003, 3, 123-123.	2.0	1
231	Approaches to dissecting mechanisms of adverse drug reactions in psychiatry: clozapine-binding sites in the bone marrow. Pharmacogenomics Journal, 2003, 3, 189-189.	2.0	2
232	Progress in psychiatric pharmacogenomics and new publication features. Pharmacogenomics Journal, 2003, 3, 249-249.	2.0	0
233	Pharmacogenomics and clinical medicine: passing flirtation or marriage?. Pharmacogenomics Journal, 2003, 3, 303-303.	2.0	5
234	The International HapMap Project. Nature, 2003, 426, 789-796.	27.8	5,735

#	Article	IF	CITATIONS
235	Identification, characterization, and gene expression profiling of endotoxin-induced myocarditis. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 14241-14246.	7.1	21
236	The Prototypic Antidepressant Drug, Imipramine, but not Hypericum perforatum (St. John's Wort), Reduces HPA-Axis Function in the Rat. Hormone and Metabolic Research, 2003, 35, 602-606.	1.5	16
237	Emergent Oscillations in Mathematical Model of the Human Menstrual Cycle. CNS Spectrums, 2003, 8, 805-814.	1.2	22
238	Cortisol feedback state governs adrenocorticotropin secretory-burst shape, frequency, and mass in a dual-waveform construct: time of day-dependent regulation. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2003, 285, R950-R961.	1.8	30
239	The interface of obesity and depression: risk factors for the metabolic. Revista Brasileira De Psiquiatria, 2003, 25, 196-197.	1.7	18
240	Cytokine Pathways in the Brain. Neurobiological Foundation of Aberrant Behaviors, 2003, , 39-53.	0.2	0
241	Autoimmunity in autism. Molecular Psychiatry, 2002, 7, 329-329.	7.9	21
242	Advances in the pharmacogenomics of adverse drug reactions. Pharmacogenomics Journal, 2002, 2, 273-273.	2.0	11
243	Patient-oriented investigation in pharmacogenomics. Pharmacogenomics Journal, 2002, 2, 137-137.	2.0	0
244	Complexity and Pharmacogenomics. Pharmacogenomics Journal, 2002, 2, 203-203.	2.0	1
245	Gene–environment interactions in Molecular Psychiatry. Molecular Psychiatry, 2002, 7, 123-124.	7.9	7
246	Progress in the genetics of autism. Molecular Psychiatry, 2002, 7, 229-229.	7.9	6
247	Will pharmacogenomics guide clinical practice?. Pharmacogenomics Journal, 2002, 2, 71-71.	2.0	2
248	New editorial policies: content and electronic submission. Molecular Psychiatry, 2002, 7, 1-1.	7.9	18
249	State of the art and electronic submission of manuscripts. Pharmacogenomics Journal, 2002, 2, 1-1.	2.0	4
250	Anorexia Nervosa and Bulimia Nervosa. , 2002, , 515-530.		0
251	The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Molecular Psychiatry, 2002, 7, 1107-1114.	7.9	203
252	Conceptualizing depression. Molecular Psychiatry, 2002, 7, 429-429.	7.9	1

#	Article	IF	CITATIONS
253	Brain-derived neurotrophic factor (BDNF) in stress and affective disorders. Molecular Psychiatry, 2002, 7, 519-519.	7.9	41
254	Depression and cardiovascular disease: co-occurrence or shared genetic substrates?. Molecular Psychiatry, 2002, 7, 1031-1032.	7.9	20
255	Informed Consent in Pharmacogenomics. Pharmacogenomics Journal, 2002, 2, 343-344.	2.0	5
256	Depression and obesity treatments are life saving. Nature Medicine, 2002, 8, 1336-1336.	30.7	3
257	Autonomic Nervous System–Leptin Interactions. , 2002, , 223-243.		0
258	FICTION: An Internet Tea Party. Science, 2001, 291, 1493-1495.	12.6	0
259	Single nucleotide polymorphism identification in candidate gene systems of obesity. Pharmacogenomics Journal, 2001, 1, 193-203.	2.0	13
260	Cytokines in the brain: From localization and function to clinical implications. NeuroImmune Biology, 2001, , 365-371.	0.2	2
261	Expression of corticotropin releasing hormone receptors type I and type II mRNA in suicide victims and controls. Molecular Psychiatry, 2001, 6, 540-546.	7.9	118
262	Research and treatment approaches to depression. Nature Reviews Neuroscience, 2001, 2, 343-351.	10.2	546
263	A feedback-controlled ensemble model of the stress-responsive hypothalamo-pituitary-adrenal axis. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 4028-4033.	7.1	137
264	Pharmacogenomics and Ethnic Minorities. Pharmacogenomics Journal, 2001, 1, 85-85.	2.0	5
265	Synchronicity of Frequently Sampled Thyrotropin (TSH) and Leptin Concentrations in Healthy Adults and Leptin-Deficient Subjects: Evidence for Possible Partial TSH Regulation by Leptin in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3284-3291.	3.6	199
266	The pharmacogenomics of depression. Pharmacogenomics Journal, 2001, 1, 175-177.	2.0	13
267	Synchronicity of Frequently Sampled Thyrotropin (TSH) and Leptin Concentrations in Healthy Adults and Leptin-Deficient Subjects: Evidence for Possible Partial TSH Regulation by Leptin in Humans. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3284-3291.	3.6	47
268	Molecular psychiatry at the millennium. Molecular Psychiatry, 2000, 5, 1-2.	7.9	3
269	Obesity: on the eve of a major conceptual revolution. Drug Discovery Today, 2000, 5, 177-179.	6.4	2
270	Leptina: o di \tilde{A}_i logo entre adip \tilde{A}^3 citos e neur \tilde{A} ´nios. Arquivos Brasileiros De Endocrinologia E Metabologia, 2000, 44, 205-214.	1.3	23

#	Article	IF	Citations
271	The neuroimmune-endocrine axis: pathophysiological implications for the central nervous system cytokines and hypothalamus-pituitary-adrenal hormone dynamics. Brazilian Journal of Medical and Biological Research, 2000, 33, 1141-1148.	1.5	39
272	Acute systemic inflammation up-regulates secretory sphingomyelinase <i>in vivo</i> : A possible link between inflammatory cytokines and atherogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8681-8686.	7.1	156
273	Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: Relation to hypercortisolism and corticotropin-releasing hormone. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 325-330.	7.1	518
274	The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress**This research was supported by NIMH Grant MH-50479 and the Undergraduate Research Opportunities Program at the University of Colorado at Boulder Endocrinology, 1999, 140, 79-86.	2.8	225
275	Circadian Interleukin-6 Secretion and Quantity and Depth of Sleep. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2603-2607.	3.6	423
276	Cytokines in affective disorders and schizophrenia: new clinical and genetic findings. Molecular Psychiatry, 1999, 4, 109-111.	7.9	16
277	The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Molecular Psychiatry, 1999, 4, 317-327.	7.9	339
278	Brain iNOS: current understanding and clinical implications. Trends in Molecular Medicine, 1999, 5, 225-232.	2.6	112
279	Human Leptin Deficiency Caused by a Missense Mutation: Multiple Endocrine Defects, Decreased Sympathetic Tone, and Immune System Dysfunction Indicate New Targets for Leptin Action, Greater Central than Peripheral Resistance to the Effects of Leptin, and Spontaneous Correction of Leptin-Mediated Defects. Iournal of Clinical Endocrinology and Metabolism. 1999. 84. 3686-3695.	3.6	627
280	NEUROSCIENCE: What Makes One Tic?. Science, 1999, 286, 56-57.	12.6	2
281	Chronic administration of the non-peptide CRH type 1 receptor antagonist antalarmin does not blunt hypothalamic-pituitary-adrenal axis responses to acute immobilization stress. Life Sciences, 1999, 65, PL53-PL58.	4.3	47
282	Tryptophan-depletion challenge in depressed patients treated with desipramine or fluoxetine: implications for the role of serotonin in the mechanism of antidepressant action. Biological Psychiatry, 1999, 46, 212-220.	1.3	274
283	The Impact of the Nonpeptide Corticotropin-Releasing Hormone Antagonist Antalarmin on Behavioral and Endocrine Responses to Stress. Endocrinology, 1999, 140, 79-86.	2.8	95
284	Human Leptin Deficiency Caused by a Missense Mutation: Multiple Endocrine Defects, Decreased Sympathetic Tone, and Immune System Dysfunction Indicate New Targets for Leptin Action, Greater Central than Peripheral Resistance to the Effects of Leptin, and Spontaneous Correction of Leptin-Mediated Defects. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3686-3695.	3.6	158
285	Circadian Interleukin-6 Secretion and Quantity and Depth of Sleep. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 2603-2607.	3.6	94
286	Molecular Psychiatry 1996: High immediacy index. Molecular Psychiatry, 1998, 3, iv-iv.	7.9	1
287	Molecular Psychiatry: D'o \tilde{A}^1 venons-nous? Que sommes-nous? O \tilde{A}^1 allons-nous?. Molecular Psychiatry, 1998, 3, 4-5.	7.9	1
288	Circumscribed lesion of the medial forebrain bundle area causes structural impairment of lymphoid organs and severe depression of immune function in rats. Molecular Psychiatry, 1998, 3, 397-404.	7.9	5

#	Article	IF	Citations
289	The nitric oxide hypothesis of aging. Experimental Gerontology, 1998, 33, 813-826.	2.8	138
290	Leptin. International Journal of Biochemistry and Cell Biology, 1998, 30, 1285-1290.	2.8	123
291	Expressing Freudian Influences. Science, 1998, 282, 2197-2198.	12.6	3
292	Longitudinally Sampled Human Plasma Leptin and Cortisol Concentrations Are Inversely Correlated. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1042-1042.	3.6	14
293	Sex Differences in Circulating Human Leptin Pulse Amplitude: Clinical Implications 1. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4140-4147.	3.6	154
294	Synchronicity of frequently sampled, 24-h concentrations of circulating leptin, luteinizing hormone, and estradiol in healthy women. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 2541-2546.	7.1	258
295	Plasma Leptin Levels Are Increased in Survivors of Acute Sepsis: Associated Loss of Diurnal Rhythm in Cortisol and Leptin Secretion. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 280-283.	3.6	95
296	Sex Differences in Circulating Human Leptin Pulse Amplitude: Clinical Implications. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 4140-4147.	3.6	123
297	Longitudinally Sampled Human Plasma Leptin and Cortisol Concentrations Are Inversely Correlated. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 1042-1042.	3.6	6
298	Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. American Journal of Psychiatry, 1997, 154, 624-629.	7.2	641
299	Interleukin (IL) 1β, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: Pathophysiological implications. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 227-232.	7.1	224
300	Endogenous Interleukin-1 Receptor Antagonist is Neuroprotective. Biochemical and Biophysical Research Communications, 1997, 234, 211-215.	2.1	136
301	Plasma Leptin Levels Do not Change in Patients with Cushing's Disease Shortly after Correction of Hypercortisolism. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2747-2750.	3.6	58
302	Cardiovascular and neuroendocrine adjustment to public speaking and mental arithmetic stressors. Psychophysiology, 1997, 34, 266-275.	2.4	370
303	Molecular psychiatry: does a new field need to examine strategy?. Molecular Psychiatry, 1997, 2, 3-4.	7.9	0
304	Interleukin 1 receptor antagonist gene expression in rat pituitary in the systemic inflammatory response syndrome: pathophysiological implications. Molecular Psychiatry, 1997, 2, 99-103.	7.9	13
305	Leptin in anorexia nervosa and amenorrhea. Molecular Psychiatry, 1997, 2, 267-269.	7.9	14
306	Forty years of neuroendocrinology: a tribute to SM McCann. Molecular Psychiatry, 1997, 2, 347-349.	7.9	0

#	Article	IF	CITATIONS
307	Biomedicine '98 â€" Call for abstracts. Molecular Psychiatry, 1997, 2, 429-429.	7.9	O
308	Human leptin levels are pulsatile and inversely related to pituitary–ardenal function. Nature Medicine, 1997, 3, 575-579.	30.7	637
309	Pathways and mechanisms for cytokine signaling of the central nervous system Journal of Clinical Investigation, 1997, 100, 2941-2947.	8.2	187
310	Leptin Levels Are Elevated Despite Low Thyroid Hormone Levels in the "Euthyroid Sick" Syndromei. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 4278-4279.	3.6	17
311	Plasma Leptin Levels Do not Change in Patients with Cushing's Disease Shortly after Correction of Hypercortisolism. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2747-2750.	3.6	41
312	The World Health Organization sponsored study group on anorexia nervosa (AN): basic mechanisms, clinical approaches and treatment. Psychiatry Research, 1996, 62, 1-2.	3.3	3
313	The hypothalamic-pituitary-adrenal axis in anorexia nervosa. Psychiatry Research, 1996, 62, 75-83.	3.3	138
314	Identification of Hypothalamic Transcripts Upregulated by Antidepressants. Biochemical and Biophysical Research Communications, 1996, 229, 275-279.	2.1	23
315	IL- $1\hat{i}^2$, IL-1 receptor type I and iNOS gene expression in rat brain vasculature and perivascular areas. NeuroReport, 1996, 7, 2445-2448.	1.2	70
316	Thyroid function in bulimia nervosa. Psychoneuroendocrinology, 1996, 21, 249-261.	2.7	20
317	Inducible nitric oxide synthase gene expression in the brain during systemic inflammation. Nature Medicine, 1996, 2, 581-584.	30.7	272
318	Interleukin $1\hat{l}^2$ and fever. Nature Medicine, 1996, 2, 1314-1315.	30.7	12
319	Cytokines in the Brain. Neuroscience Intelligence Unit, 1996, , 3-20.	0.5	7
320	Focal cerebral ischemia induces CRH mRNA in rat cerebral cortex and amygdala. NeuroReport, 1995, 6, 1785-1788.	1.2	50
321	Corticotropin Releasing Hormone in the Pathophysiology of Melancholic and Atypical Depression and in the Mechanism of Action of Antidepressant Drugs. Annals of the New York Academy of Sciences, 1995, 771, 716-729.	3.8	189
322	Localization of Interleukin- $1\hat{l}^2$ P Converting Enzyme mRNA in Rat Brain Vasculature: Evidence that the Genes Encoding the Interleukin-1 System Are Constitutively Expressed in Brain Blood Vessels. NeuroImmunoModulation, 1995, 2, 141-148.	1.8	47
323	Overview of Neuroimmune Stress Interactions Annals of the New York Academy of Sciences, 1995, 771, 364-371.	3.8	41
324	A molecular mechanism for stress-induced alterations in susceptibility to disease. Lancet, The, 1995, 346, 104-106.	13.7	36

#	Article	IF	CITATIONS
325	The gene encoding for the novel transacting factor proopiomelanocortin corticotropin-releasing hormone responsive element binding protein 1 (PCRH-REB-1) is constitutively expressed in rat pituitary and in discrete brain regions containing CRH or CRH receptors: pathophysiological implications. Endocrinology, 1995, 136, 4709-4712.	2.8	1
326	Pulsatility of 24-Hour Concentrations of Circulating Interleukin-1-Alpha in Healthy Women: Analysis of Integrated Basal Levels, Discrete Pulse Properties, and Correlation with Simultaneous Interleukin-2 Concentrations. NeuroImmunoModulation, 1994, 1, 242-250.	1.8	6
327	Localization of Interleukin 1 Type I Receptor mRNA in Rat Brain. NeuroImmunoModulation, 1994, 1, 110-115.	1.8	115
328	Effects of sleep deprivation on serotonin function in depression. Biological Psychiatry, 1994, 36, 840-846.	1.3	57
329	Localization of Stem Cell Factor mRNA in Adult Rat Hippocampus. NeuroImmunoModulation, 1994, 1, 181-187.	1.8	20
330	Localization of corticotropin-releasing hormone (CRH) receptor mRNA in adult rat brain by in situ hybridization histochemistry. Endocrinology, 1994, 135, 2275-2278.	2.8	33
331	Activity-induced anorexia in rats does not affect hypothalamic neuropeptide gene expression chronically. International Journal of Eating Disorders, 1993, 13, 399-405.	4.0	19
332	Differential effects of kindled and electrically induced seizures on a glutamate receptor (GluR1) gene expression. Epilepsy Research, 1993, 14, 221-227.	1.6	59
333	In Situ Hybridization Techniques for Localization of Interleukin 1 and Interleukin 1 Receptor Antagonist mRNA in Brain. Methods in Neurosciences, 1993, 16, 81-99.	0.5	3
334	Neutrophil-activating peptide-1 /interleukin-8 mRNA is localized in rat hypothalamus and hippocampus. NeuroReport, 1992, 3, 753-756.	1.2	25
335	Induction of constitutive heat shock protein 73 mRNA in the dentate gyrus by seizures. Molecular Brain Research, 1992, 13, 19-25.	2.3	28
336	4 Role of corticotrophin releasing hormone 41 in depressive illness. Bailliere's Clinical Endocrinology and Metabolism, 1991, 5, 51-58.	1.0	12
337	Elevated central levels of interleukin-2 in drug-free schizophrenic patients. Schizophrenia Research, 1991, 4, 372.	2.0	13
338	Decrease in resting metabolic rate during abstinence from bulimic behavior. American Journal of Psychiatry, 1991, 148, 1071-1072.	7.2	22
339	Localization of Interleukin-1 Receptor Antagonist mRNA in Rat Brain. Endocrinology, 1991, 129, 562-564.	2.8	113
340	Insulin secretion in eating disorders. Biological Psychiatry, 1989, 25, A20.	1.3	0
341	The Effect of Biosynthetic Human Proinsulin on the Hepatic Response to Glucagon in Insulin-Deficient Diabetes*. Journal of Clinical Endocrinology and Metabolism, 1987, 64, 476-481.	3.6	12
342	Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients Journal of Clinical Investigation, 1986, 77, 98-105.	8.2	330

=	#	Article	IF	CITATIONS
	343	Pharmacological interventions for the treatment of depression in chronic obstructive pulmonary disease. The Cochrane Library, 0, , .	2.8	3
:	344	Psychological therapies for the treatment of depression in chronic obstructive pulmonary disease. The Cochrane Library, 0, , .	2.8	5